Treatment of hepatitis C virus infection in the future.
Treatment of hepatitis C virus infection in the future.
复制标题
DOI：
10.1186/2001-1326-2-9
复制
发表时间：
2013-04-11
影响因子：
10.6
通讯作者：
Omata M
中科院分区：
文献类型：
--
作者：
Kanda T;Yokosuka O;Omata M
两种针对丙型肝炎病毒（HCV）的直接作用抗病毒药物（DAAs）：特拉匹韦（telaprevir）和波昔普韦（boceprevir），现在可与聚乙二醇干扰素加利巴韦林联合用于治疗慢性丙型肝炎感染。虽然这些药物是HCV复制的有效抑制剂，但它们偶尔会导致严重的不良事件。在目前的临床试验中，正在研究几种第二代daa。大多数药物都被寄予厚望，但它们也需要与聚乙二醇干扰素和利巴韦林联合使用。在不久的将来，我们可能会使用全口服DAAs和无干扰素方案来治疗HCV感染患者，这些方案将是HCV的有效抑制剂，并且不良事件较少。
Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second-generation DAAs are being investigated. Most of them are being viewed with high expectations, but they also require the combination with peginterferon plus ribavirin. In the near future, we might be using all-oral DAAs and interferon-free regimens for the treatment of HCV-infected patients, and these would be potent inhibitors of HCV and have less adverse events.